Sign up
Pharma Capital

Follow up study points to 'even bigger opportunity' for Traumakine - Faron Pharma CEO

Dr Markku Jalkanen, CEO of Faron Pharmaceuticals Oy (LON:FARN), tells Proactive London's Andrew Scott they believe unexpectedly high corticosteroid (steroid hormones) use by some patients may have affected the results of its Traumakine INTEREST study.

The Phase III study into acute respiratory distress syndrome (ARDS) yielded a disappointing result in May but further experiments by Faron have opened up the possibility that corticosteroids used in parallel to Traumakine treatment affected Traumakine’s (FP-1201-lyo) efficacy.

 

View full FARN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.